^Paredes SD, Korkmaz A, Manchester LC, Tan DX, Reiter RJ (2009). “Phytomelatonin: a review”. J. Exp. Bot.60 (1): 57–69. doi:10.1093/jxb/ern284.
PMID19033551.
^Boutin JA, Audinot V, Ferry G, Delagrange P (August 2005). “Molecular tools to study melatonin pathways and actions”. Trends Pharmacol. Sci.26 (8): 412–9. doi:10.1016/j.tips.2005.06.006.
PMID15992934.
^Hardeland R (July 2005). “Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance”. Endocrine27 (2): 119–30. doi:10.1385/ENDO:27:2:119.
PMID16217125.
^Reiter RJ, Acuña-Castroviejo D, Tan DX, Burkhardt S; Acuña-Castroviejo; Tan; Burkhardt (June 2001). “Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system”. Ann. N. Y. Acad. Sci.939: 200–15. Bibcode: 2001NYASA.939..200R. doi:10.1111/j.1749-6632.2001.tb03627.x.
PMID11462772.
^Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T (2004年11月). “Melatonin for treatment of sleep disorders”. Evidence Report/Technology Assessment No. 108. (Prepared by the University of Alberta Evidence-based Practice Center, under Contract No. 290-02-0023.) AHRQ Publication No. 05-E002-2. Rockville, MD: Agency for Healthcare Research and Quality. Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services. 2013年6月5日閲覧。
^ abEuropean Medicines Agency. “Circadin, melatonin”. European Public Assessment Report (EPAR). European Medicines Agency. 2013年6月5日閲覧。
^ abReiter RJ (May 1991). “Pineal melatonin: cell biology of its synthesis and of its physiological interactions”. Endocr. Rev.12 (2): 151–80. doi:10.1210/edrv-12-2-151.
PMID1649044.
^Richardson GS (2005). “The human circadian system in normal and disordered sleep”. J Clin Psychiatry66 Suppl 9: 3–9; quiz 42–3.
PMID16336035.
^Perreau-Lenz S, Pévet P, Buijs RM, Kalsbeek A (January 2004). “The biological clock: the bodyguard of temporal homeostasis”. Chronobiol. Int.21 (1): 1–25. doi:10.1081/CBI-120027984.
PMID15129821.
^Ardura J, Gutierrez R, Andres J, Agapito T (2003). “Emergence and evolution of the circadian rhythm of melatonin in children”. Horm. Res.59 (2): 66–72. doi:10.1159/000068571.
PMID12589109.
^Gavin ML, Scaivina MT (March 2013 2009 エラー: 日付を year と date に分けずに date にまとめて記入してください。(説明)). “Why Aren't Teens Getting Enough Sleep?” (英語). How Much Sleep Do I Need?. The Nemours Foundation. 2017年2月10日閲覧。
^Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E, Rollag MD (August 2001). “Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor”. J. Neurosci.21 (16): 6405–12.
PMID11487664.
^Kayumov L, Casper RF, Hawa RJ, Perelman B, Chung SA, Sokalsky S, Shapiro CM (May 2005). “Blocking low-wavelength light prevents nocturnal melatonin suppression with no adverse effect on performance during simulated shift work”. J. Clin. Endocrinol. Metab.90 (5): 2755–61. doi:10.1210/jc.2004-2062.
PMID15713707.
^Burkhart K, Phelps JR. (26 December 2009). “Amber lenses to block blue light and improve sleep: a randomized trial”. Chronobiol Int26 (8): 1602–12. doi:10.3109/07420520903523719.
PMID20030543.
^Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC (October 2005). “Phase-dependent treatment of delayed sleep phase syndrome with melatonin”. Sleep28 (10): 1271–8.
PMID16295212.
^Terman MR, Wirz-Justice A (2009). Chronotherapeutics for Affective Disorders: A Clinician's Manual for Light and Wake Therapy. Basel: S Karger Pub. p. 71.
ISBN3-8055-9120-9
^ abVecchierini MF, Kilic-Huck U, Quera-Salva MA (2021-3). “Melatonin (MEL) and its use in neurological diseases and insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS)”. Rev Neurol (Paris)177 (3): 245–259. doi:10.1016/j.neurol.2020.06.009.
PMID32921425.